Search

A preprint abstract from medrxiv.org discusses the 2022 Sudan Ebolavirus outbreak in Uganda, where an outbreak of Sudan virus (SUDV) was confirmed. Researchers developed a modelling platform to estimate the burden of cases, deaths, and the duration of the outbreak, with projections aligning with observed outcomes. This research has not yet undergone peer review and can be found at medrxiv.org/content/10.1101/2024.10.11.24314870v1. The study focuses on virology, epidemiology, and viral hemorrhagic diseases, providing valuable insights into the outbreak. [Extracted from the article]

The article focuses on research from the University of Texas Medical Branch that investigates the effectiveness of Obeldesivir (ODV) in protecting nonhuman primates from Sudan Ebolavirus (SUDV). Topics include the antiviral activity of ODV and its metabolite GS-441524 against filoviruses, the 100% protection conferred by oral ODV treatment in cynomolgus monkeys, and the implications for rapid outbreak control of filovirus diseases.

A recent study conducted by the Uganda Public Health Fellowship Program examined the prevalence of mental health disorders among individuals affected by the 2022 Sudan virus disease (SVD) outbreak in Uganda. The study found that approximately two-thirds of SVD survivors and family members experienced anxiety, depression, or post-traumatic stress disorder (PTSD) shortly after the outbreak ended. Factors such as household size and the number of SVD deaths in the household were associated with these mental health disorders. The researchers suggest that strengthening mental health services during and after Ebola virus outbreaks could improve the quality of outbreak response. [Extracted from the article]

Researchers at the University of Hawaii Manoa have developed a thermostable bivalent filovirus vaccine that protects against severe and lethal Sudan ebolavirus and Marburgvirus infection. The vaccine consists of recombinant glycoproteins formulated with a clinical-grade oil-in-water nanoemulsion adjuvant. In tests on cynomolgus macaques, the vaccine provided 100% protection against filovirus disease after infection with either Sudan ebolavirus or Marburgvirus. These results demonstrate the potential of thermostabilized protein vaccines in addressing the gap in preparedness for future filovirus outbreaks. [Extracted from the article]

Geovax Inc. has been granted a patent for a vaccine that aims to prevent and treat diseases caused by hemorrhagic fever viruses such as Ebola, Marburg, and Lassa. The patent focuses on the development of countermeasures against these highly pathogenic viruses, which have caused outbreaks and resulted in severe illness and death. The vaccine uses a modified vaccinia Ankara (MVA) vector that contains genetic sequences for glycoproteins and matrix proteins from these viruses. This vaccine could potentially provide a much-needed solution to the lack of licensed vaccines for these deadly viruses. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of a multi-pathogen vaccine targeting Zaire ebolavirus, Sudan ebolavirus, Marburg, and Lassa viruses. Viral hemorrhagic fevers caused by these viruses have resulted in significant morbidity and mortality in West and Central Africa. The researchers utilized two viral vectored vaccine platforms, an adenovirus and Modified Vaccinia Ankara, to develop the vaccine. The study shows that the multi-pathogen vaccine induces strong cellular and humoral immunity and provides protection against lethal challenges of Zaire ebolavirus, Sudan ebolavirus, and Marburg virus in a small animal model. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

The recombinant MVA vector of claim 22, wherein the first nucleic acid encoding the Sudan ebolavirus glycoprotein comprises nucleic acids 1631-3664 of SEQ ID NO: 13, and the or a nucleic acid sequence at least 95% identical thereto, second nucleic acid sequence encoding the Zaire ebolavirus VP40 matrix protein comprises SEQ ID NO: 9." The recombinant MVA vector of claim 20, wherein the first nucleic acid encoding the Sudan ebolavirus glycoprotein comprises nucleic acids 1631-3664 of SEQ ID NO: 13, and the or a nucleic acid sequence at least 95% identical thereto, second nucleic acid sequence encoding the Zaire ebolavirus VP40 matrix protein comprises SEQ ID NO: 9. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40). [Extracted from the article]